<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	anorexia
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Eating Disorders
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Emaciation, Cyanosis, Ataxia, Learning Disorders, Spasm
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Phosphoric acid</td>
		<td>Approved</td>
		<td>Phosphoric acid is used in dentistry and orthodontics as an etching solution, to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed.</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Citalopram</td>
		<td>Approved</td>
		<td>For the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA Label]. </td>
	</tr>	<tr>
		<td>3.</td>
		<td>Nesiritide</td>
		<td>Approved, Investigational</td>
		<td>For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Exenatide</td>
		<td>Approved, Investigational</td>
		<td>Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Paroxetine</td>
		<td>Approved, Investigational</td>
		<td>Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause. </td>
	</tr>	<tr>
		<td>6.</td>
		<td>VSF-173</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in sleep disorders.</td>
	</tr>	<tr>
		<td>7.</td>
		<td>Facinicline</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, neurologic disorders, and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>8.</td>
		<td>JB991</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in psoriasis and psoriatic disorders and skin infections/disorders.</td>
	</tr>	<tr>
		<td>9.</td>
		<td>SGS518</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in neurologic disorders and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>10.</td>
		<td>Diethylpropion</td>
		<td>Approved, Illicit</td>
		<td>Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.</td>
	</tr>	<tr>
		<td>11.</td>
		<td>prGCD</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in metabolic disease and neurologic disorders.</td>
	</tr>	<tr>
		<td>12.</td>
		<td>TD-2749</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in constipation, gastrointestinal diseases and disorders (miscellaneous), gastroparesis, and irritable bowel syndrome (IBS).</td>
	</tr>	<tr>
		<td>13.</td>
		<td>LU-31130</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Col-118</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in skin infections/disorders.</td>
	</tr>	<tr>
		<td>15.</td>
		<td>RPI-78M</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in multiple sclerosis, neurologic disorders, and pain (acute or chronic).</td>
	</tr>	<tr>
		<td>16.</td>
		<td>Mito-4509</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, neurologic disorders, parkinson's disease, and retinal disorders (unspecified).</td>
	</tr>	<tr>
		<td>17.</td>
		<td>ABT-560</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in neurologic disorders.</td>
	</tr>	<tr>
		<td>18.</td>
		<td>Sotirimod</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in actinic keratosis and skin infections/disorders.</td>
	</tr>	<tr>
		<td>19.</td>
		<td>LX6171</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), dementia, neurologic disorders, and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>20.</td>
		<td>Opebacan</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in crohn's disease, congenital anomaly (unspecified), cardiovascular disorders, pediatric indications, and burns and burn infections.</td>
	</tr>	<tr>
		<td>21.</td>
		<td>GW 597599</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in adverse effects (chemotherapy), anxiety disorders, depression, and gastrointestinal diseases and disorders (miscellaneous).</td>
	</tr>	<tr>
		<td>22.</td>
		<td>Ilodecakin</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in inflammatory disorders (unspecified), crohn's disease, and rheumatoid arthritis.</td>
	</tr>	<tr>
		<td>23.</td>
		<td>Dasotraline</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>24.</td>
		<td>Samidorphan</td>
		<td>Investigational</td>
		<td>Not Available</td>
	</tr>	<tr>
		<td>25.</td>
		<td>PH-284</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in anorexia and other conditions causing harmful weight loss. The manufacturer suggests it could be relevant for treatment of weight loss and the associated symptoms-- i.e., lack of energy, decrease in appetite, physical wasting, vulnerability to toxicity, and sometimes reduced life expectancy-- in patients with eating disorders, patients with advanced cancer, patients with AIDS, and patients experiencing loss of appetite due to aging, acute illness, or pregnancy.</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>